Immunoglobulin E specific for Cladosporium herbarum allergens (sIgE (C. herbarum))

Immunoglobulin E (IgE) antibodies specific for Cladosporium herbarum allergens are the primary mediators of allergic reactions to this ubiquitous environmental mold (PubMed: 11485323). Cladosporium herbarum is a major source of fungal allergens, with Cla h 1 being the most significant major allergen recognized by IgE in sensitized individuals (UniProt: P42097). These specific IgE antibodies circulate in the blood and bind to high-affinity FcεRI receptors on mast cells and basophils. When the individual is re-exposed to Cladosporium spores, the allergens cross-link the IgE-FcεRI complexes, leading to the degranulation of inflammatory mediators that cause symptoms of allergic rhinitis and asthma (NIH: StatPearls - Type I Hypersensitivity). Therapeutic interventions include omalizumab, a monoclonal antibody that binds to the Fc region of IgE, thereby preventing its interaction with receptors and reducing the allergic response (PubChem: CID 160786). Additionally, allergen-specific immunotherapy (AIT) is used to induce immunological tolerance by modulating the production of these specific IgE antibodies and increasing protective IgG4 levels (PubMed: 28024484). Monitoring the levels of these specific IgE antibodies is crucial for diagnosing mold allergy and assessing the efficacy of treatment interventions. The presence of these antibodies is often associated with more severe respiratory symptoms and a higher risk of asthma exacerbations. Cross-reactivity between Cladosporium IgE and other fungal species like Alternaria can complicate diagnosis and management. Overall, these antibodies represent a critical target for both diagnostic testing and therapeutic management in allergic diseases.

Other names

Cladosporium herbarum-specific IgEAnti-Cladosporium herbarum IgEm2-specific IgEIgE to Cla h 1

Anti-IgE monoclonal antibodies, such as omalizumab, bind to the Cε3 domain of the IgE heavy chain, which is the site of interaction with the high-affinity FcεRI receptor. This sequestration prevents allergen-specific IgE from sensitizing mast cells and basophils (PubMed: 24565708). Allergen-specific immunotherapy (AIT) works by exposing the patient to increasing doses of Cladosporium allergens to induce regulatory T cells and shift the antibody profile from IgE to IgG4 (PubMed: 28024484).